T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology-Reference-Cited by-同舟云学术

T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology

Published:2022-03 Issue:3 Volume:20 Page:285-308
ISSN:1540-1405
Container-title:Journal of the National Comprehensive Cancer Network
language:
Short-container-title:

Author:

Horwitz Steven M.¹,Ansell Stephen²,Ai Weiyun Z.³,Barnes Jeffrey⁴,Barta Stefan K.⁵,Brammer Jonathan⁶,Clemens Mark W.⁷,Dogan Ahmet¹,Foss Francine⁸,Ghione Paola⁹,Goodman Aaron M.¹⁰,Guitart Joan¹¹,Halwani Ahmad¹²,Haverkos Bradley M.¹³,Hoppe Richard T.¹⁴,Jacobsen Eric¹⁵,Jagadeesh Deepa¹⁶,Jones Allison¹⁷,Kallam Avyakta¹⁸,Kim Youn H.¹⁴,Kumar Kiran¹⁹,Mehta-Shah Neha²⁰,Olsen Elise A.²¹,Rajguru Saurabh A.²²,Rozati Sima²³,Said Jonathan²⁴,Shaver Aaron²⁵,Shea Lauren²⁶,Shinohara Michi M.²⁷,Sokol Lubomir²⁸,Torres-Cabala Carlos⁷,Wilcox Ryan²⁹,Wu Peggy³⁰,Zain Jasmine³¹,Dwyer Mary³²,Sundar Hema³²

Affiliation:

1. 1Memorial Sloan Kettering Cancer Center;

2. 2Mayo Clinic Cancer Center;

3. 3UCSF Helen Diller Family Comprehensive Cancer Center;

4. 4Massachusetts General Hospital Cancer Center;

5. 5Abramson Cancer Center at the University of Pennsylvania;

6. 6The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;

7. 7The University of Texas MD Anderson Cancer Center;

8. 8Yale Cancer Center/Smilow Cancer Hospital;

9. 9Roswell Park Comprehensive Cancer Center;

10. 10UC San Diego Moores Cancer Center;

11. 11Robert H. Lurie Comprehensive Cancer Center of Northwestern University;

12. 12Huntsman Cancer Institute at the University of Utah;

13. 13University of Colorado Cancer Center;

14. 14Stanford Cancer Institute;

15. 15Dana-Farber/Brigham and Women's Cancer Center;

16. 16Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;

17. 17St. Jude Children's Research Hospital/The University of Tennessee Health Science Center;

18. 18Fred & Pamela Buffett Cancer Center;

19. 19UT Southwestern Simmons Comprehensive Cancer Center;

20. 20Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;

21. 21Duke Cancer Institute;

22. 22University of Wisconsin Carbone Cancer Center;

23. 23The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;

24. 24UCLA Jonsson Comprehensive Cancer Center;

25. 25Vanderbilt-Ingram Cancer Center;

26. 26O'Neal Comprehensive Cancer Center at UAB;

27. 27Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance;

28. 28Moffitt Cancer Center;

29. 29University of Michigan Rogel Cancer Center;

30. 30UC Davis Comprehensive Cancer Center;

31. 31City of Hope National Medical Center; and

32. 32National Comprehensive Cancer Network.

Abstract

Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of lymphoproliferative disorders arising from mature T cells, accounting for about 10% of non-Hodgkin lymphomas. PTCL-not otherwise specified is the most common subtype, followed by angioimmunoblastic T-cell lymphoma, anaplastic large cell lymphoma, anaplastic lymphoma kinase–positive, anaplastic large cell lymphoma, anaplastic lymphoma kinase–negative, and enteropathy-associated T-cell lymphoma. This discussion section focuses on the diagnosis and treatment of PTCLs as outlined in the NCCN Guidelines for T-Cell Lymphomas.

Publisher

Harborside Press, LLC

Subject

Oncology

Link

https://jnccn.org/downloadpdf/journals/jnccn/20/3/article-p285.xml

Reference266 articles.

1. Second-line therapy with ICE followed by high dose therapy and autologous stem cell transplantation for relapsed/refractory peripheral T-cell lymphomas: minimal benefit when analyzed by intent to treat [abstract];Horwitz;Blood,2005

2. Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center;Gale;J Clin Oncol,2000

3. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial;Morschhauser;Eur J Cancer,2013

4. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin;Horwitz;Blood,2014

5. Cyclosporine treatment of angioimmunoblastic T-cell lymphoma relapsed after an autologous hematopoietic stem cell transplant;Wang;Exp Clin Transplant,2015

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Aggressive T‐cell lymphomas: 2024: Updates on diagnosis, risk stratification, and management;American Journal of Hematology;2024-02-02

2. SOHO State-of-the-Art Updates and Next Questions: Treatment for Newly Diagnosed Peripheral T-Cell Lymphomas;Clinical Lymphoma Myeloma and Leukemia;2024-02

3. Primary Cutaneous CD30-Positive Lymphoproliferative Disorders—Current Therapeutic Approaches with a Focus on Brentuximab Vedotin;Journal of Clinical Medicine;2024-01-31

4. The difference of double-positive T cells and double-negative-T cells in myeloid neoplasms before and after chemotherapy, and after COVID-19 infection;2024-01-19

5. IgG antibody response to SARS-CoV-2 infection and its influencing factors in lymphoma patients;BMC Immunology;2024-01-13